List of Incivek drug patents
Incivek is owned by Vertex Pharms.
Incivek contains Telaprevir.
Incivek has a total of 2 drug patents out of which 0 drug patents have expired.
Incivek was authorised for market use on 23 May, 2011.
Incivek is available in tablet;oral dosage forms.
Incivek can be used as method of treating chronic hepatitis c.
The generics of Incivek are possible to be released after 30 May, 2028.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(5 years from now) | |
Drugs and Companies using TELAPREVIR ingredient
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic